NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp(NMTC)股票分析

$1.610

-0.085 (-5.29%)收盘时

Loading chart…
High
1.720
Open
1.670
VWAP
1.64
Vol
71.50K
Mkt Cap
20.69M
Low
1.600
Amount
117.49K
EV/EBITDA, TTM
-0.88

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures.

nmtc1.com

AI analysis of NeuroOne Medical Technologies Corp (NMTC)

buy

Neuroone Medical Technologies Corp is a good buy right now due to its recent product revenue growth of 72% year-over-year, reaching $2.4 million, and an improved gross margin of 59.9%, which indicates strong market demand and operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.25, which reflects ongoing profitability challenges.

估值指标

The current forward P/E ratio for NeuroOne Medical Technologies Corp (NMTC) is 0.00, compared to its 5-year average forward P/E of -2.90.

Forward P/E

Strongly Overvalued
5Y Average P/E
-2.90
Current P/E
0.00
高估
-1.73
低估
-4.07

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-1.31
Current EV/EBITDA
-0.88
高估
-0.21
低估
-2.40

Forward P/S

Fair
5Y Average P/S
26.86
Current P/S
1.21
高估
132.52
低估
-78.80

事件时间线

2026-04-15 (ET)

19:50:00

NeuroOne Medical Technologies Trading Halted, News Pending

2025-08-18 (ET)

08:33:30

NeuroOne Medical Secures FDA 510(k) Approval for OneRF Device

2025-08-14 (ET)

07:39:35

NeuroOne Medical sees FY25 product revenue $8M-$10M vs. $3.5M last year

07:39:22

NeuroOne Medical reports Q3 EPS (3c) vs. (10c) last year

2025-07-23 (ET)

08:41:36

NeuroOne Medical receives notice of allowance for key patent from USPTO

资讯

NMTC FAQ — answered by Alphio AI

NeuroOne Medical Technologies Corporation is a medical technology company. It is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. It may also pursue applications for other areas such as depression, mood disorders, incontinence and artificial intelligence. Its products include Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, and OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Neuroone Medical Technologies Corp is a good buy right now due to its recent product revenue growth of 72% year-over-year, reaching $2.4 million, and an improved gross margin of 59.9%, which indicates strong market demand and operational efficiency. However, the main risk is the negative earnings per share (EPS) of -0.25, which reflects ongoing profitability challenges.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始